Found 220 clinical trials
Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors (STELLAR-002)
administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet), and nivolumab + bempegaldesleukin (triplet) in subjects with advanced solid tumors. In the Expansion
- 0 views
- 25 Apr, 2022
- 1 location
Axitinib + Ipilimumab in Advanced Melanoma
The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.
- 0 views
- 24 Mar, 2022
- 1 location
NeoVax Plus Ipilimumab in Renal Cell Carcinoma
will be involved in this study: Personalized Neoantigen Vaccine Poly-ICLC (Hiltonol) Ipilimumab
- 0 views
- 08 Apr, 2022
Ipilimumab for Head and Neck Cancer Patients
This study is for patients with squamous cell carcinoma of the head and neck (SCCHN). This study will test the feasibility of the administration of intratumoral injections of ipilimumab prior to
- 0 views
- 24 Mar, 2022
- 1 location
Surgical Nivolumab And Ipilimumab For Recurrent GBM
This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the
- 0 views
- 22 Mar, 2022
- 2 locations
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
This research is being done to study the effects of the combination of ipilimumab, nivolumab, and radiation therapy in people with microsatellite stable pancreatic cancer. The names of
- 0 views
- 25 Jan, 2021
Infliximab for Treatment of Ipilimumab Colitis
This research study is evaluating the effectiveness and safety of infliximab therapy compared with steroids in the treatment of ipilimumab-induced colitis in patients with III/IV melanoma.
- 10 views
- 06 Nov, 2021
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (CHINOREC)
This prospective randomized, open-label, multicenter, phase II clinical trial investigates the safety and tolerability of standard neoadjuvant chemoradiotherapy (CRT) with sequential ipilimumab
- 0 views
- 19 Apr, 2022
- 5 locations
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in
- 14 views
- 25 Mar, 2022
- 1 location
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (CYTOSHRINK)
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the
- 0 views
- 23 Apr, 2022
- 6 locations